TG Therapeutics, Inc.
US ˙ NasdaqCM ˙ US88322Q1085

SecurityTGTX / TG Therapeutics, Inc.
InstitutionRYDEX VARIABLE TRUST - Biotechnology Fund Variable Annuity
Latest Disclosed Ownership2,642 shares
Latest Disclosed Value $ 95,085
RYDEX VARIABLE TRUST - Biotechnology Fund Variable Annuity reports 0.30% decrease in ownership of TGTX / TG Therapeutics, Inc.

On August 27, 2025 - RYDEX VARIABLE TRUST - Biotechnology Fund Variable Annuity filed a NPORT-P form disclosing ownership of 2,642 shares of TG Therapeutics, Inc. (US:TGTX) valued at $95,086 USD as of June 30, 2025. The entity filed a previous NPORT-P on May 29, 2025 disclosing 2,650 shares of TG Therapeutics, Inc.. This represents a change in shares of -0.30% during the quarter. The current value of the position is $107,160 USD.

Institutional Ownership: 13F and NPORT Filings

The Security and Class in the table below are shown exactly as filed by the investor. We do our best to track continuity of investments through acquisitions, and this will be reflected in the table as changes in names. In addition to descriptive data, performance of the investment is shown over time. To calculate quarterly performance, we first calculate cost basis of the shares purchased during the quarter, then use that to calculate gross profit. Quarterly return is Gross Profit / Starting Portfolio value.

Note that cost basis is calculated and stored in thousands, so small quarterly changes in shares frequently result in a cost basis of zero.

Upgrade to unlock premium data and export to Excel .

Disclosed Equity Positions (from 13F/NPORT Filings)
File
Date
Effective
Date
Form Security Class ID Avg Price
Paid (Est)
Reported
Shares
ΔShares ΔShares
(%)
Reported
Value
(x1000)
ΔValue
(%)
Alloc
(%)
ΔAlloc ΔAlloc (%) Cost Basis
(x1000)
Unrealized
Gain/Loss
(x1000)
2025-08-27 2025-06-30 NP TG Therapeutics EC US88322Q1085 2,642 -8 -0.30 95 -8.65 1.0567
2025-05-29 2025-03-31 NP TG Therapeutics EC US88322Q1085 2,650 -398 -13.06 104 14.29 1.1100
2025-03-03 2024-12-31 NP TG Therapeutics EC US88322Q1085 3,048 -869 -22.19 92 0.00 0.9197
2024-11-29 2024-09-30 NP TG Therapeutics EC US88322Q1085 3,917 -772 -16.46 92 9.64 0.8298
2024-08-29 2024-06-30 NP TG Therapeutics EC US88322Q1085 4,689 -557 -10.62 83 5.06 0.7605
2024-05-30 2024-03-31 NP TG Therapeutics EC US88322Q1085 5,246 131 2.56 80 -9.20 0.6767
2024-02-29 2023-12-31 NP TG Therapeutics EC US88322Q1085 5,115 -1,871 -26.78 87 50.00 0.7160
2023-11-29 2023-09-30 NP TG Therapeutics EC US88322Q1085 6,986 2,446 53.88 58 -48.21 0.5057
2023-08-28 2023-06-30 NP TG Therapeutics EC US88322Q1085 4,540 -1,627 -26.38 113 21.74 0.8900
2023-05-30 2023-03-31 NP TG Therapeutics EC US88322Q1085 6,167 -3,895 -38.71 93 -3.16 0.7025
2022-05-26 2022-03-31 NP TG Therapeutics EC US88322Q1085 10,062 865 9.41 96 -45.40 0.5654
2022-02-28 2021-12-31 NP TG Therapeutics EC US88322Q1085 9,197 2,931 46.78 175 -16.35 0.7722
2021-11-29 2021-09-30 NP TG Therapeutics EC US88322Q1085 6,266 467 8.05 209 -7.14 0.8766
2021-08-27 2021-06-30 NP TG Therapeutics EC US88322Q1085 5,799 383 7.07 225 -14.18 0.9421
2021-05-27 2021-03-31 NP TG Therapeutics EC US88322Q1085 5,416 5,416 261 1.1747
Legend
Shares
The total number of shares held by the institution at the end of the reporting period (the effective date). This is provided in the filing.
Value
The total value of the shares as of the effective date. This is provided in the filing.
Avg. Share Price
The weighted average share price of the shares held by the institution. We use FIFO accounting to determine this price
Class
This is the security class as indicated by the filer. There are a variety of values for this field. Common values include "EC" = equity common, "EP" - equity preferred
Allocation (%)
The percent of the institution's portfolio that this position represents. This is provided in NPORT filings. For 13F filings, we calculate it.
Change in Allocation
The change in allocation from the prior reporting period. This is calculated as current allocation - prior allocation.
Change in Allocation (%)
The percent change in allocation from the prior reporting period. This is calculated as (current allocation - prior allocation) / prior allocation.
Cost Basis
The total cost of the shares held. This is calculated as reported shares * avg. share price
Unrealized Gain/Loss
This is the market value of the position as of the effective date minus the cost basis.